@article{34f71e00487b436fbe80efd3d81dd9d0,
title = "A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose",
abstract = "Oral and intravenous (IV) N-acetylcysteine (NAC) are used for the treatment of acetaminophen poisoning. The objective of this multicenter study was to compare the safety of these two routes of administration. Methods. We conducted a multicenter chart review of all patients treated with NAC for acetaminophen poisoning. The primary safety outcome was the percentage of patients with NAC-related adverse events. Results. A total of 503 subjects were included in the safety analysis (306 IV-only, 145 oral-only, and 52 both routes). There were no serious adverse events related to NAC for either route. Nausea and vomiting were the most common related adverse events and were more common with oral treatment (23 vs. 9). Anaphylactoid reactions were more common with IV administration (6 vs. 2). Conclusions. IV and oral NAC are generally mild adverse drug reactions. copyright",
keywords = "Acetaminophen, Acute poisoning, N-Acetylcysteine",
author = "Bebarta, \{V. S.\} and L. Kao and B. Froberg and Clark, \{R. F.\} and E. Lavonas and M. Qi and J. Delgado and J. McDonagh and T. Arnold and O. Odujebe and G. O'Malley and C. Lares and E. Aguilera and R. Dart and K. Heard and C. Stanford and J. Kokko and G. Bogdan and C. Mendoza and S. Mlynarchek and S. Rhyee and J. Hoppe and W. Haur and Tan, \{H. H.\} and Tran, \{N. N.\} and S. Varney and A. Zosel and J. Buchanan and M. Al-Helial",
note = "Funding Information: This project was supported by the 2004 American College of Clinical Toxicology Multi-Center Research Grant and an unrestricted research grant from Cumberland Pharmaceuticals. Rocky Mountain Poison and Drug Center (RMPDC) was the coordinating center for this multi-center study. All funds were paid out to the participating centers and RMPDC received no support for this project. RMPDC has clinical, consulting, and research contracts with Cumberland Pharmaceuticals (a manufacturer of IV acetylcysteine) and McNeil Consumer Healthcare (a manufacturer of acetaminophen products). The investigators were responsible for the design, performance, and analysis of the study and for the drafting and revisions of the manuscript. The sponsors had no role in the study design, performance, and did not review the manuscript prior to acceptance. Dr. Heard was supported by Award Number K08DA020573 from the National Institute on Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.",
year = "2010",
month = jun,
doi = "10.3109/15563650.2010.486381",
language = "English (US)",
volume = "48",
pages = "424--430",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Taylor and Francis Ltd.",
number = "5",
}